Agreement formed to evaluate combination therapy for pancreatic cancer

An agreement has been formed between XBiotech and Cedars-Sinai Medical Center to perform a study evaluating the interleukin-1 alpha antagonist, MABp1, in combination with Onivyde and 5-fluorouracil/folinic acid to treat pancreatic cancer.

The study, to be led by Dr Andrew Hendifar (medical oncology lead for the Gastrointestinal Disease Research Group at Cedars-Sinai and co-director of Pancreas Oncology), is planned to enrol 16 patients with advanced pancreatic adenocarcinoma and cachexia. Patients will be administered intravenously with MABp1 in combination with the maximum tolerated dose of Onivyde (Irinotecan liposome injection) and 5-fluorouracil/folinic acid every two weeks until disease progression. It is hoped that this combination therapy will help to control disease, reduce symptoms and allow patients to receive treatment for longer, thereby improving outcomes.

“The results to date with treatment of MABp1 show much promise as an effective therapy in this setting,” commented Hendifar. “I look forward to evaluating this combination therapy to determine its safety and clinical benefit.”

Additionally, this study will assess the efficacy of the combination therapy through various secondary measures, such as changes in lean body mass, weight stability, IL-6 levels, overall and progression free survival as well as evaluation of the relationship between treatment tolerance and patient functional status.

XBiotech is a global biosciences company dedicated to the discovery, development and commercialisation of therapeutic antibodies based on its True Human proprietary technology.